Exfoliation syndrome (XFS) is the most common known risk factor for secondary glaucoma and a major cause of blindness worldwide. Variants in two genes, LOXL1 and CACNA1A, have previously been associated with XFS. To further elucidate the genetic basis of XFS, we collected a global sample of XFS cases to refine the association at LOXL1, which previously showed inconsistent results across populations, and to identify new variants associated with XFS. We identified a rare protective allele at LOXL1 (p.Phe407, odds ratio (OR) = 25, P = 2.9 × 10 −14 ) through deep resequencing of XFS cases and controls from nine countries. A genome-wide association study (GWAS) of XFS cases and controls from 24 countries followed by replication in 18 countries identified seven genome-wide significant loci (P < 5 × 10 −8 ). We identified association signals at 13q12 (POMP), 11q23.3 (TMEM136), 6p21 (AGPAT1), 3p24 (RBMS3) and 5q23 (near SEMA6A). These findings provide biological insights into the pathology of XFS and highlight a potential role for naturally occurring rare LOXL1 variants in disease biology.
XFS is an age-related systemic disorder involving the extracellular matrix (ECM). It is characterized by the excessive production and progressive accumulation of an abnormal extracellular material in various tissues 1 . Manifesting most conspicuously in the eye, XFS is the most common cause of secondary glaucoma worldwide 2 and is also a prognostic factor for progression of open-angle glaucoma 3 . This disease is common in many populations, with an estimated 60-70 million individuals affected [4] [5] [6] [7] . Exfoliation glaucoma (XFG) has a worse prognosis than other major types of glaucoma, and it is often resistant to intraocular-pressure-lowering medical treatment, more often requiring laser and surgical intervention 3, 8 . Cumulatively, XFS and XFG represent a major cause of blindness globally.
The strong pattern of familial aggregation for XFS indicates substantial genetic contribution to disease pathology 9, 10 ; and LOXL1, a gene encoding lysyl oxidase homolog 1, was the first genetic locus reported to be associated with this disease 11 . Despite the overwhelming strength of the genetic association seen at polymorphisms mapping to LOXL1, the results are inconsistent owing to risk alleles being 'flipped' in certain populations 12, 13 . Such stark allele reversals imply that the genetic architecture underlying XFS disease biology is complex and worthy of further study.
Recently, CACNA1A was identified as the second locus associated with XFS 14 . Realizing that large and inclusive international collaborative efforts are essential in providing new biological leads in complex disease pathogenesis [15] [16] [17] [18] [19] [20] , we report here a worldwide collaborative XFS study aimed at further understanding the genetic basis of the disorder. First, because of the allele reversals seen for common polymorphisms at LOXL1 led by rs3825942[G>A] (p.Gly153Asp) and, to a lesser extent, rs1048661 [T>G] (p.Leu141Arg) 12, [21] [22] [23] [24] [25] [26] [27] [28] ( Supplementary Fig. 1 ), we aimed to refine the LOXL1 genetic landscape by performing deep sequencing of the entire gene in 5,570 XFS and XFG cases and 6,279 controls from nine countries (Supplementary Table 1 ). The previously reported CACNA1A locus was also sequenced to assess whether rare variants in the gene encoding nonsynonymous amino acid substitutions could provide further insights [29] [30] [31] . In our effort to identify additional genetic variants associated with XFS, we also conducted an expanded GWAS of 13,838 cases and 110,275 controls from countries across six continents (Supplementary Figs. 2 and 3, and Supplementary Table 2 ).
RESULTS

A rare missense variant in LOXL1 protects against XFS
We conducted deep resequencing of the entire LOXL1 and CACNA1A loci (Online Methods) in 5,570 XFS cases and 6,279 controls. This sequencing effort confirmed previously reported strong allele reversals at key common variants and also at recently reported noncoding variants in LOXL1 (Supplementary Tables 3-5) 13, 21, 23 .
We first analyzed the sequencing data to find unifying, consistent common variants associated with XFS across ancestry groups that could have been missed by previous efforts. Single-variant analysis showed that, of all common variants polymorphic across all collections studied, rs3825942 [G>A] (encoding LOXL1 p.Gly153Asp) remained the most significantly associated (fixed-effects P = 4.14 × 10 −62 ) but showed very high heterogeneity across the study groups (random-effects P = 0.0039). No common variant in LOXL1 was consistently associated across all the collections, and no common variant in this gene surpassed genome-wide significance in random-effects analysis (Supplementary Table 6 ). Conditioning for allele dosage at rs3825942 [G>A] abolished all residual evidence of association across the collections (Supplementary Table 6 ). The commonly reported rs1048661 [T>G] (p.Leu141Arg) polymorphism was not significant in the meta-analysis of sequencing data either before (P = 0.25) or after 9 9 4 VOLUME 49 | NUMBER 7 | JULY 2017 Nature GeNetics A r t i c l e s (P = 0.53) conditioning on rs3825942[G>A] (P het < 1 × 10 −10 ; I 2 = 98.3%). Recognizing that single-variant analysis could have missed a consistent LOXL1 haplotypic association that is not reversed across populations, we followed up our search by phasing the haplotypes of 57 SNPs across the entire sequenced LOXL1 locus using 20-SNP sliding windows. All analyzed haplotypes showed reversal of effect across the locus, with no exceptions (Supplementary Data 1). It is thus unlikely that we have missed an 'unflipped' common variant that shows consistent association with XFS across our worldwide sample.
The resequencing of LOXL1 identified a total of 63 unique nonsynonymous variants across the nine countries studied ( Supplementary  Fig. 4 and Supplementary Table 7) . Because of the limited insights available from the reversed common LOXL1 haplotypes, we next evaluated the hypothesis that rare alleles within LOXL1 (minor allele frequency (MAF) < 1%) could collectively contribute to XFS risk. We observed a broad enrichment for rare nonsynonymous LOXL1 variants in the normal controls in comparison to the XFS cases (OR = 0.46, P = 4.2 × 10 −7 ; Table 1 ). As the vast majority of the nonsynonymous variants did not exert functional effects [31] [32] [33] [34] , we performed a second test restricting the analysis to aggregate only rare nonsynonymous variants conservatively predicted to be deleterious by all five of the functional effect prediction algorithms used (SIFT, PolyPhen-2-HumDiv, LRT score, MutationTaster and Condel) 33 . In so doing, we observed a substantially larger protective effect conferred by the rare variant burden (OR = 0.18, P = 4.23 × 10 −11 ; Table 2 ). This protective effect of alleles conservatively predicted to affect LOXL1 function remained significant even after accounting for cosegregation at the rs3825942[G>A] sentinel SNP (Supplementary Table 8 ).
One of the rare nonsynonymous variants, rs201011613[A>T], encoding LOXL1 p.Tyr407Phe, showed genome-wide significant association in single-variant analysis. This variant was conservatively predicted by all five protein function prediction algorithms to affect LOXL1 function and is found exclusively in the Japanese population ( Table  3 , Supplementary Fig. 4a ,b and Supplementary Table 7) . The rare rs201011613[T] (LOXL1 p.407Phe) allele was observed in only 2 of the 3,909 XFS cases (0.026%) but was observed in 68 of the 5,338 age-and hospital-matched controls with no eye disorder (0.64%) ( Table 3) , conferring 25-fold resistance to XFS (Fisher's exact test, P = 2.9 × 10 −14 ). We examined individuals carrying the rare p.Phe407 allele who had also undergone genome-wide genotyping for the presence of population substructure but found no evidence that these carriers clustered along the major axes of population stratification (Supplementary Fig. 5 ) 35, 36 .
We next examined the haplotype background for all 37 Japanese individuals carrying the p.407Phe allele who underwent sequencing for the LOXL1 locus ( Table 3 ) and found that, in 35 of the 37 individuals, the p.Phe407 allele segregated with the common rs3825942[A] (p.Asp153) haplotype. As previously discussed, this common rs3825942[A] haplotype was associated with protection from XFS in Japan but conferred susceptibility to XFS in black Africans and was thus only nominally significant in the meta-analysis of all collections that underwent LOXL1 resequencing (random-effects P = 0.0039; Supplementary Table 3 ). Although the rare, protective p.Phe407 allele does not segregate with the common p.Arg141Leu polymorphism, functional biological testing would be needed to assess the relative impact of all three nonsynonymous variants (at amino acid positions 141, 153 and 407) on LOXL1 function. No additional filters by functional effect prediction algorithm were applied. Frequencies for rare variant carriers are given as percentages. L95, lower 95% confidence limit; U95, upper 95% confidence limit. Variants were tagged as deleterious by five functional prediction algorithms (SIFT, PolyPhen-2-HumDiv, LRT score, MutationTaster and Condel). Frequencies for rare variant carriers are given as percentages. NA, not possible to estimate because of zero counts in cases.
a Excluding collections where no rare, deleterious nonsynonymous substitutions were found in either cases or controls.
A r t i c l e s
At the CACNA1A locus, a total of 200 unique rare nonsynonymous amino acid substitutions were observed in the coding sequence of CACNA1A after resequencing in East Asians, Europeans, South Africans and South Asians. In contrast to LOXL1, we did not observe any consistent evidence of association between rare variant burden at CACNA1A and susceptibility to XFS (Supplementary Table 9 ). This is not surprising, as only some common variant GWAS loci harbor an additional rare variant burden 37 .
Biological relevance of LOXL1 p.Tyr407Phe XFS is characterized by excessive production and progressive accumulation of an abnormal fibrillar material, termed exfoliation material, containing ECM components such as elastin, fibrillin-1 and fibronectin, localized to the surface of various cell types including lens epithelial cells 1, 38, 39 . LOXL1 has been reported to modulate ECM biogenesis by cross-linking elastin and collagen in connective tissues [40] [41] [42] . We thus performed experiments assaying the effects of LOXL1 variants A r t i c l e s on ECM metabolism, using elastin, fibrillin-1, collagen type IV and fibronectin as cellular biochemical readouts and overall relative cell adhesion as a cellular physiological readout.
We assessed the functional effects of the common flipped p.Arg141Leu and p.Gly153Asp polymorphisms as well as the rare, protective p.Tyr407Phe variant using four constructs carrying these three variants in naturally occurring haplotypes (Fig. 1a) . This experimental design also allowed for measurement of the effect of p.Tyr407Phe while conditioning on the effects of all p.Arg141Leu-p.Gly153Asp haplotype combinations. The ability to condition on and account for the effect of p.Gly153Asp is particularly important as the rare, protective p.Phe407 allele segregates with the p.Asp153 allele. Using human lens epithelial cell (HLEC) 3D cell cultures transiently expressing the four haplotypes, we observed that LOXL1 protein was secreted at detectable levels, and no significant difference in LOXL1 secretion could be observed between any of the four haplotypes ( Supplementary Fig. 6a) .
In contrast, when we overexpressed the rare p.Phe407-carrying Arg141-Asp153-Phe407 (G-A-T) LOXL1 haplotype in HLEC cultures, we observed a dose-dependent increase in elastin levels on immunoblots ( Supplementary Fig. 6b ), with the increase in elastin levels recapitulated in immunofluorescence analysis of 3D spheroid cultures (Fig. 1b) . Overexpression of this rare p.Phe407-carrying haplotype also resulted in a decrease in collagen IV levels ( Fig. 1c) and an increase in fibrillin-1 levels ( Fig. 1d ) when compared to the other three haplotypes that included the wild-type p.Tyr407 allele. This result suggests that the rare p.Phe407 allele has an overall upregulating effect on ECM components such as elastin and fibrillin.
As the ECM is important for cellular adhesion, we next asked whether these observed functional biochemical effects of the rare LOXL1 p.Phe407 allele on ECM components in vitro would translate to a physiological outcome affecting cell-cell adhesion. To this end, HLEC 3D spheroids overexpressing the four haplotypes were analyzed for relative cellular adhesion strength using the microelectrodes of the Roche xCelligence real-time cell analysis system. In this methodology, the change in cellular impedance readout is directly proportional to the quality of cell attachment [43] [44] [45] . We observed that the rare, protective p.Phe407-carrying G-A-T LOXL1 haplotype conferred a significant increase in the strength of cellular adhesion in comparison to the remaining three haplotypes carrying the wild-type p.Tyr407 allele (P < 0.01 for all comparisons; Fig. 1e ). We observed no significant difference in the relative strength of cellular adhesion when the three remaining haplotypes carrying p.Tyr407 (but with different combinations of the p.Arg141Leu and p.Gly153Asp alleles) were compared to one another (Fig. 1e) , suggesting that the common p.Arg141Leu and p.Gly153Asp polymorphisms do not have a significant effect on the strength of cellular adhesion in this assay. To ensure that the increase in the strength of cell-cell adhesion was unique to the rare, protective p.Phe407 (rs201011613[T]) allele, two additional LOXL1 haplotype constructs covering the G-G-T (Arg141-Gly153-Phe407) and T-G-T (Leu141-Gly153-Phe407) haplotypes were cloned. We retested all six haplotype constructs together for differences in cell-cell adhesion (Supplementary Fig. 7 ) and continued to observe that the introduction of the rare, protective p.Phe407 (rs201011613[T]) allele significantly increased physiological cellcell adhesion irrespective of the p.Arg141Leu and p.Gly153Asp background alleles. In contrast, the haplotypes carrying the wildtype, baseline p.Tyr407 (rs201011613[A]) allele had significantly lower cell-cell adhesion, also irrespective of the p.Arg141Leu and p.Gly153Asp alleles (P < 1 × 10 −4 for all comparisons, unpaired t test; Supplementary Fig. 7 ).
GWAS identifies five new loci associated with XFS
As XFS is a complex disease, we also sought to identify new genetic loci associated with this disorder. For the GWAS discovery stage, we directly genotyped a total of 9,035 XFS cases and 17,008 controls, enrolled from 24 countries across six continents, using the Illumina OmniExpress BeadChip (Supplementary Table 2 ). After quality checks, we were able to analyze 683,397 directly genotyped autosomal SNP markers for association with XFS disease status (Supplementary Data 2) (see the Supplementary Note for full detail).
The GWAS discovery meta-analysis identified consistent and significant association (OR = 1.17, P = 2.97 × 10 −10 , I 2 = 0%; Supplementary Fig. 8 ) at a new locus defined by SNP rs7329408 mapping to FLT1-POMP-SLC46A3 on chromosome 13. We also observed a clear excess of smaller than expected P values at the tail end of the quantile-quantile distribution (P ≤ 1 × 10 −4 ; Supplementary Fig. 8 ; refs. 37, 46, 47) , suggesting that there are additional loci to be identified. We took forward all markers showing P ≤ 1 × 10 −4 in the GWAS discovery stage for further assessment in the replication stage (see Supplementary Table 10 for power calculations) comprising 4,803 XFS cases and 93,267 controls independently ascertained from 18 countries (Supplementary Table 2 ). SNPs at five distinct new loci showed consistent evidence of replication, and meta-analysis of all 13,838 cases and 110,275 controls from the GWAS and replication series demonstrated genome-wide significant association at the five loci (1.56 × 10 −16 ≤ P ≤ 1.5 × 10 −8 ; Fig. 2 , Table 4 and Supplementary  Fig. 9 ; see Supplementary Table 11 for ancestry-and geographystratified analysis of the five new loci). These loci are FLT1-POMP-SLC46A3 (rs7329408; chromosome 13), TMEM136-ARHGEF12 (rs11827818; chromosome 11), AGPAT1 (rs3130283; chromosome 6), RBMS3 (rs12490863; chromosome 3) and SEMA6A (rs10072088; chromosome 5). Regional association maps showing the genomic organization of the five loci within a 1-Mb region flanking the sentinel SNP are appended as Supplementary Figure 10 . We verified that the genotyping was of good quality at the sentinel SNPs for all five loci (Supplementary Fig. 11 ). We also confirmed genome-wide significant association at the previously reported CACNA1A marker, rs4926244 (Supplementary ratio of the risk allele highest in polar regions and lowest in equatorial regions (Supplementary Table 13 and Supplementary Note).
Biological insights from GWAS associated loci
We annotated 33 genes mapping to or located closest to the seven genome-wide significant loci (identified using the 150,000-bp genomic region centered on the sentinel SNP and SNP markers showing r 2 > 0.5 with the sentinel SNP (Supplementary Table 14) or defined by credible set analysis 37, 48, 49 ; Online Methods). Except for rs3130283 in the AGPAT locus, which is located within the broad major histocompatibility complex (MHC) locus on chromosome 6 that is well known to have long-range complex LD patterns, we observed that defining an 'associated locus region' either generically as the region within 150 kb of the index variant or as the region containing proxy SNPs with r 2 > 0.5 with the index variant resulted in identification of the same genes ( Supplementary Fig. 10 and Supplementary Table 14) . All credible sets for the seven genome-wide significant loci were located within relatively narrow genomic regions (<100,000 bp) and within the region formed by the proxy SNPs showing r 2 > 0.5 with the index variant (inclusive of the index variant; Supplementary Table 14) . We next assessed the potential biological contribution for each of the 33 genes by determining whether these genes showed overlap with (i) genes expressed in anterior segment tissues such as the iris and ciliary body, as determined using publicly available databases [50] [51] [52] [53] [54] , (ii) genes associated with relevant eye-related phenotypes in knockout mice, (iii) genes whose expression is regulated by cis expression quantitative trait loci (eQTLs) 55, 56 , (iv) genes prioritized by text mining in PubMed, (v) genes showing pleiotropy with other forms of glaucoma and (vi) genes highlighted from unbiased genome-wide molecular pathway analysis. We summarize this additional information in Supplementary Table 15 . A genome-wide search using publicly available databases 57 identified potential molecular interactions between the proteins encoded by several of the 33 genes located within the seven genome-wide significant loci (Supplementary Table 15) , suggesting that the significantly associated loci could be implicating broader, yet-undescribed biological disease pathways. A search of the UCSC Genome Browser showed that none of the seven genome-wide significant loci harbor any long noncoding RNAs except for LOXL1 (which harbors LOXL1-AS1, transcribed in the opposite direction from LOXL1) and the FLT1-POMP-SLC46A3 locus ( Supplementary  Fig. 12 ). Further interrogation using the INRICH (interval-based enrichment analysis tool) software package 58 , designed to detect enriched association signals for LD-independent genomic regions within biologically relevant gene sets, did not identify any statistically significant biological pathways highlighted by the seven genome-wide significant loci (Supplementary Data 3) .
We next studied the expression of genes associated with the three most significantly associated loci. These loci (and genes) were 13q12 (POMP, FLT1, SLC46A3), 11q23.3 (TMEM136, ARHGEF12) and 6p21 (AGPAT1). Expression for these six genes was tested in fresh ocular tissues obtained from human donor eyes with appropriate research consent (Online Methods). For mRNA expression analyses, 41 normal eyes with no known ocular disease (mean age, 77.1 ± 8.1 years; 20 female, 21 male) and 21 eyes with XFS (mean age, 80.1 ± 7.9 years; 11 female, 10 male) were used. mRNA expression of all six genes was detected at moderate levels in the panel of eye tissues analyzed (Supplementary Fig. 13 ). The highest expression levels were observed in tissues relevant for the synthesis of exfoliation material (iris and ciliary body) and for glaucoma pathophysiology (retina). Expression levels in these tissues did not significantly correlate with the genotypes of the sentinel SNPs underlying the three loci (Supplementary Fig. 14) .
Comparing tissues from XFS and control eyes, the mRNA expression levels of POMP and TMEM136 were significantly reduced by up to 41% in anterior segment tissues, such as iris and ciliary body, from XFS eyes in comparison to age-matched control eyes ( Supplementary  Fig. 15 ). These results in XFS-relevant tissues suggest that POMP (rather than FLT1 and SLC46A3, which are located nearby) is the likely disease-related gene for the chromosome 13 locus and that TMEM136 (rather than the neighboring ARHGEF12) is the likely disease-related gene for the chromosome 11 locus.
POMP and TMEM136 protein expression was further analyzed by immunoblotting and immunofluorescence microscopy. POMP, a proteasome maturation protein, was expressed in most ocular cell types in immunofluorescence analysis (Fig. 3) . However, POMP protein levels were significantly reduced in iris (45% decrease) and ciliary Reduced staining intensity in XFS tissues is associated with LOXL1-positive exfoliation material accumulations (red immunofluorescence) on the surface of the iris pigment epithelium (k), ciliary epithelium (m) and iris blood vessel walls (m). Immunoblots (cropped images) and densitometry analysis show reduced POMP protein expression in iris and ciliary body tissue lysates of XFS eyes as compared to control eyes (g). Data are shown as the POMP/β-actin ratio (n = 6 for each group; mean ± s.d.; *P < 0.01, **P < 0.005, unpaired two-sided t test); uncropped versions of all immunoblots are shown in supplementary Figure 16 . BV, blood vessel; CE, ciliary epithelium, CoE, corneal epithelium; DM, descemet membrane; GCL, retinal ganglion cell layer; INL, inner nuclear layer; IPE, iris pigment epithelium; LE, limbal epithelium; ONL, outer nuclear layer; SC, Schlemm's canal; ST, stroma; TM, trabecular meshwork. DAPI nuclear counterstaining is shown in blue. Scale bars, 100 µm in c, d and f and 20 µm in a, b, e and h-m. Reduced TMEM136 protein expression levels in iris and ciliary body tissues of XFS eyes as compared to age-matched controls shown by immunoblot analysis (g) and immunofluorescence labeling of iridal (h,k) and ciliary (i,l) epithelia, as well as vascular endothelia in the iris (j,m). Reduced staining intensity in XFS tissues is associated with LOXL1-positive exfoliation material accumulations (red immunofluorescence) on the surface of the iris pigment epithelium (k), ciliary epithelium (l) and iris blood vessel walls (m). Immunoblots (cropped images) and densitometry analysis show reduced TMEM136 protein (isoform 1 at 28 KDa and isoform 3 at 31 KDa) expression in iris and ciliary body tissue lysates of XFS eyes as compared to control eyes (g). Data are shown as the TMEM136/β-actin ratio (mean ± s.d.; n = 6 for each group; *P < 0.01, **P < 0.005, unpaired two-sided t test); uncropped versions of all immunoblots are shown in supplementary Figure 17 . AV, aqueous vein; BV, blood vessel; CE, ciliary epithelium; DIL, dilator muscle; GCL, retinal ganglion cell layer; INL, inner nuclear layer; IPE, iris pigment epithelium; LE, limbal epithelium; ONL, outer nuclear layer; SC, Schlemm's canal; ST, stroma; TM, trabecular meshwork. DAPI nuclear counterstaining is in blue. Scale bars, 200 µm in a, 100 µm in b-f and 20 µm in h-m.
A r t i c l e s body (33% decrease) specimens from XFS eyes in comparison to control eyes when protein expression was investigated by immunoblot analysis (Fig. 3g and Supplementary Fig. 16 ) and immunofluorescence microscopy ( Fig. 3h-m) . These results are consistent with the differential mRNA expression shown in Supplementary Figure 15 . TMEM136, a transmembrane protein of unknown function, was primarily localized by immunofluorescence to the vascular endothelial cells of blood vessels in eye tissues (Fig. 4) . Analysis of TMEM136 protein levels by immunoblotting in tissues from XFS eyes showed significantly reduced expression levels in iris (26% decrease) and ciliary body (32% decrease) in comparison to the levels observed in control eyes ( Fig. 4g and Supplementary Fig. 17 ), also consistent with the differential mRNA expression analysis shown in Supplementary Figure  15 . Similar findings of reduced TMEM136 protein staining in epithelial and endothelial cells in XFS eyes in comparison to control eyes were also obtained using immunofluorescence microscopy ( Fig. 4h-m) .
We then replicated the immunofluorescence microscopy findings in tissues from a further three donor eyes with XFS and three matched controls using an independent batch of antibodies, co-staining for LOXL1, POMP and TMEM136. We confirmed reduced expression of POMP and TMEM136 in important ocular anterior segment structures in XFS eyes in comparison to control eyes, using both low magnification (Supplementary Fig. 18 ) and higher magnification ( Supplementary Figs. 19 and 20) .
DISCUSSION
XFS is a disorder of aging involving the ECM, with LOXL1 hypothesized to have a central role in disease pathogenesis. As all common LOXL1 haplotypes detected by the resequencing effort showed reversal of genetic effect, the functional consequences of these haplotypes remain in doubt. Even a recent study describing a region in intron 1 of LOXL1 and 5′ upstream of LOXL1-AS1 containing a promoter that influences LOXL1-AS1 expression showed that all strongly associated variants influencing the promoter activity of LOXL1-AS1 also had genome-wide significant reversal of the genetic effect 21 . The common allele reversals at LOXL1 are unlikely to be due to sampling differences within the same population in light of multiple replications confirming these reversals. They are also unlikely to be due to different LD structures across different populations, as the reversals occur across all phased haplotypes along the broad LOXL1 locus (Supplementary Data 1) in the absence of gross differences in LD architecture (Supplementary Fig. 21 ).
Deep resequencing of LOXL1 enabled us to observe that the rare p.Tyr407Phe variant had a protective effect strong enough (resistance OR = 25) to surpass genome-wide significance on its own. Although the effect is strong, the protection provided is not absolute, as the variant was observed in two XFS cases. Both cases also carried a copy of the rs11827818[G] risk allele in the TMEM136 locus, in keeping with XFS being a complex disease. Our experiments confirm a clear functional and physiological role for the rare p.Phe407 allele, but the roles of the common p.Gly153Asp and p.Leu141Arg polymorphisms are less clear.
The protective p.Tyr407Phe substitution is located in the evolutionarily conserved catalytic domain of LOXL1 (ref. 59 ). Follow-up biological experiments suggest that the protective effect may be a consequence of stabilization of the ECM due to increased elastin and fibrillin-1 deposition. This notion is supported by histopathological observations of decreased elastic fiber formation and tissue stiffness, as well as impaired cell adhesion, in the ocular tissues of patients with XFS 60, 61 . We speculate that carrying the rare, protective p.Tyr407 variant could maintain cellular integrity and render cells more resistant to environmental stressors that destabilize or disrupt the ECM. One limitation of this approach is that the biological mechanisms for p.Tyr407Phe were not tested at the RNA level, which might be relevant as there is a possibility that p.Tyr407Phe could affect RNA stability [62] [63] [64] .
The seven loci emerging from the GWAS do not implicate a single pathogenesis pathway, supporting the hypothesis that XFS is a complex systemic disease of aging that can arise from genetic lesions in multiple pathways and different tissue types. For example, the marked downregulation of POMP (Fig. 3) , a ubiquitously expressed proteasome maturation protein, in XFS tissues suggests a reduction of ubiquitin-conjugating enzymes in XFS tissues 65 . Abnormalities in the closely related autophagy pathway, a process that also involves ubiquitin-proteasome signaling 66, 67 , have also been implicated in XFS 68 . TMEM136 expression was predominantly localized to vascular endothelia. Interestingly, a pronounced and early vasculopathy, partly involving deposition of XFS material around ocular blood vessels (Fig. 4) , appears to have a major role in XFS pathophysiology 69, 70 .
In this study, we identified three XFS susceptibility loci in addition to POMP and TMEM136, which map to AGPAT1 in the class III MHC region (6p21), to RBMS3 (3p24) and near SEMA6A (5q23). In the CHARGE consortium, AGPAT1 has been identified as a susceptibility locus for omega-6 (n-6) polyunsaturated fatty acid (PUFA) levels, which may be related to cardiovascular risk in aging populations 71 . The MHC locus (where AGPAT1 resides) has also been reported to be involved in conditions such as Alzheimer's and Parkinson's disease 72, 73 , which, like XFS, are age-related conditions. Although the biological roles of AGPAT1, RBMS3 and SEMA6A are not well understood, the consistent evidence of association at these loci opens up further avenues for research into XFS disease biology.
In summary, we now show that a rare LOXL1 variant, p.Tyr407Phe, strongly protects against XFS, raising the possibility of potential pharmacological targeting of LOXL1 for therapeutic purposes 29, [74] [75] [76] . In addition, we have identified five new XFS-associated loci that implicate new biological pathways that could be important for disease pathogenesis.
URLs. PLINK software, http://zzz.bwh.harvard.edu/plink/; R statistical program package, https://www.r-project.org/; IMPUTE2 software, https://mathgen.stats.ox.ac.uk/impute/impute_v2.html; power calculator for genetic association studies, http://zzz.bwh.harvard.edu/gpc/; Primer3 software, http://primer3.ut.ee.
METhODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. 
ONLINE METhODS
Patient collections. DNA and tissue samples from all patients with XFS and exfoliation glaucoma together with normal controls without XFS were obtained after informed written consent from each participant. All human samples were obtained in strict adherence to the tenets of the Declaration of Helsinki. All study sites obtained approval from their respective institutional review board or ethics committee. Details for each XFS case-control collection are appended in the Supplementary Note.
Genotyping of samples.
For the GWAS discovery stage performed in 24 countries (considered to be from across 25 strata owing to Russia contributing two distinct collections, one from St. Petersburg and one from the Republic of Bashkortostan; Supplementary Table 2), genome-wide genotyping was undertaken using the Illumina OmniExpress BeadChip, as previously described 14 .
To minimize bias between different genotyping arrays and platforms, all 9,035 XFS cases and 17,008 controls for the GWAS discovery stage were genotyped using the Illumina OmniExpress array, ensuring that the primary discovery analysis used only directly genotyped SNP markers uniformly genotyped in cases and controls. The absence of imputation in the primary discovery analysis means that issues relating to imputation uncertainty and insufficient information content for imputed SNPs with varying minor allele frequencies across the different ancestry groups were minimized 77 .
The replication stage included XFS collections from 18 countries (Supplementary Table 2 ). Details on the genotyping and analysis for the replication stage are appended in the Supplementary Note.
Statistical analysis for the GWAS discovery stage Stringent quality control checks were performed for each SNP marker and each individual sample. Our statistical analysis protocol for the GWAS discovery stage only included directly genotyped SNP markers genotyped by the Illumina OmniExpress BeadChip. We removed poorly performing SNP markers that showed genotyping completion rates of <95%, as well as SNPs showing significant deviation from Hardy-Weinberg equilibrium (P < 1 × 10 −6 for deviation). SNPs with a minor allele frequency of <1% were also removed from further GWAS discovery analysis. Each sample was similarly checked, and those with a poor genotyping success rate (defined as genotyping completeness < 95%), showing excess heterozygosity (defined as being >3 s.d. from the mean 78, 79 ) and having outlying genetic ancestry (defined by being more than 6 s.d. from the mean on principal-component analysis 80 ) were excluded from further analysis.
We verified the biological relationships of all samples remaining after further exclusion of samples using the principle of variability in allele sharing. We used PLINK software (see URLs) to derive information for identify-by-state status for each sample pair comparison. For each sample pair showing evidence of cryptic relatedness (IBD > 0.1875) 78 , the sample with the lower genotyping completeness rate was removed from further analysis.
We performed principal-component analysis to assess the degree of genetic stratification and population substructure for all samples that underwent genome-wide genotyping, as previously described 80 . Principal-component analysis was performed for each country/site separately to remove samples with outlying ancestry from further analysis. Principal-component scores were than calculated from a pruned set of unlinked markers (defined by pairwise r 2 < 0.1) for each country/site separately. These scores were used as covariates to adjust for residual population stratification. Principal-component plots were generated using the R statistical software package (see URLs).
Association between SNP genotypes and XFS disease status was measured using logistic regression for each separate country strata before meta-analysis was conducted, as described elsewhere 15, 81, 82 . For the GWAS discovery stage, association analysis was additionally adjusted for the first three principal components of genetic stratification for sample collections to minimize residual population stratification. The genome-wide association summary statistics of all SNP markers from the GWAS are appended as Supplementary Data 2. The genomic inflation estimate (λ GC ) was calculated using only directly genotyped SNPs, using the median regression test statistic, which is distributed in a χ 2 manner 83 . λ GC is listed for each individual GWAS discovery stratum (and also illustrated in Supplementary Fig. 22 ) as well as for the GWAS meta-analysis (Supplementary Table 2 ). In line with well-described methodologies, results for the seven genome-wide significant loci underwent double-GC correction, which corrects for genomic inflation first at the individual population stratum and then once again during meta-analysis 84, 85 .
Meta-analysis was performed via the inverse-variance, fixed-effects model using genomic control-corrected summary results (adjusted odds ratios and standard errors) from each separate country/site. At no point in the analysis were samples pooled within or across continental groups for association analysis, as this measure would not appropriately account for population stratification. The meta-analysis method validated strong reversal at LOXL1 (Supplementary Fig. 23 ).
Statistical analysis for the replication stage. SNPs showing association with XFS surpassing P ≤ 1 × 10 −4 in the GWAS discovery stage were brought forward to the replication stage and analyzed in a manner similar to the discovery stage (Supplementary Note).
Genotype imputation. For the five newly identified genome-wide significant loci, we sought to improve on the genetic resolution provided by the directly genotyped SNPs currently included on standard-content GWAS arrays via imputation fine-mapping using samples and SNP markers passing strict quality control checks. This would also allow for better delineation of the credible sets underlying each of the five newly identified loci 48 . Imputation and phasing of genotypes were carried out using IMPUTE2 software (see URLs) with the reference panel constructed from cosmopolitan population haplotypes based on data obtained from 2,535 individuals from 26 distinct populations around the world. These data are part of the 1000 Genomes Project Phase 3 (June 2014) release, as described elsewhere. To minimize the effect of imputation uncertainty, we only included imputed genotypes with an information score of ≥0.95. Allele dosages were used for the imputed data association analyses with SNPTEST software to average across imputation uncertainty.
Credible set analysis. Credible sets of SNPs were defined, as previously described, as the minimum number of genetic variants that accounted for >95% of the probability of driving each locus-specific association signal 48, 49 . For construction of credible sets, we included all genotyped variants with genotyping success rates of >95% and minor allele frequency >1%. Fine-mapping imputation variants were included using similar thresholds of minor allele frequency >1% and imputation information content >0.95 to reduce the impact of imputation quality on the credible set analysis. For the fine-mapping imputation step, allele dosages were used for the imputed data association analyses with SNPTEST software to average across imputation uncertainty.
Statistical test for interaction with geographical latitude. Statistical tests for interaction between genetic markers and geographical latitude were undertaken for the five newly identified loci showing genome-wide significant association with XFS. The odds ratio and standard error for the odds ratio estimate for each SNP tested were assigned a latitude band for the country (or zone, whichever was more precise) from which XFS cases and controls were drawn (Supplementary Table 2 ).
The odds ratios and standard errors used in this test had already undergone adjustment for principal-component analysis and genomic control correction during the GWAS analysis. We then conducted a trend test to assess whether the odds ratios for disease increased with increasing 10° increments of geographical latitude.
Mouse model phenotypes. For the 33 genes implicated by the seven genomewide significant SNPs in seven distinct loci (Supplementary Table 15) , we performed lookups in the Mouse Genome Informatics publicly available database 86 . The output was manually checked and curated, with the relevant references detailing the mouse models appended as footnotes, in Supplementary Table 15. Deep sequencing of LOXL1 and CACNA1A. Deep sequencing was performed on a total of 5,570 XFS cases and 6,279 controls from nine countries (Supplementary Table 1) . Both the LOXL1 and CACNA1A genetic loci (exons, introns, 5′ and 3′ flanking regions) spanning coordinates chr15:74,200,000 to 74,260,000 and chr19:13,307,000 to 13,745,000 were captured using the Roche NimbleGen SeqCap Easy probe kit. Enrichment and amplification of the libraries were then carried out using well-described, routine laboratory techniques 36 . Sequencing was performed using 2 × 101-bp paired-end reads on the Illumina HiSeq 2500 platform. We required that >95% of the samples be covered by at least 10× 87 . Mean coverage for sequencing across the samples was observed to be 60×.
For the analysis of LOXL1 p.Tyr407Phe, the initial 2,827 cases and 3,013 controls from Japan who underwent resequencing were enrolled from December 2007 to January 2015. A further 1,082 XFS cases and 2,325 controls from Japan were enrolled for the replication stage. These samples were collected between February 2015 and December 2016 and did not undergo deep sequencing of the entire LOXL1 locus.
Read mapping, variant detection and annotation. All sequence reads in each individual were aligned to the human reference genome (hg19) using Burrows-Wheeler aligner software, which is well described 36 . Consensus genotypes were called using the GATK best-practices guidelines. Only high-quality variants assigned 'PASS' scores by variant quality score recalibration and individuals with variant genotype calling completeness >95% were brought forward for further statistical analysis.
Power calculations for genetic association studies. Power calculations for the GWAS discovery and replication stages were performed with an additive genetic model using well-described methods (see URLs) and are shown in Supplementary Table 10. These power calculations take into account the asymmetric number of cases and controls, as is well reported in genetic association studies 82, 88 .
Haplotype phasing for the LOXL1 locus. To ensure accurate phasing to reliably capture both common and rare haplotypes, we only included individuals with a genotype call completeness rate of 100% from both the sequencing and GWAS experiments. LOXL1 haplotypes were phased using the BEAGLE 89 and PLINK 90 software packages, as previously described 35 .
Tissue specimens for analysis of the GWAS loci. Human donor eyes used for corneal transplantation with appropriate research consent were obtained and processed within 15 h of death. For RNA and DNA extractions, 21 donor eyes with XFS (mean age, 80.1 ± 7.9 years; 11 female, 10 male) and 41 normal, healthy, age-matched control eyes (mean age, 77.1 ± 8.1 years; 20 female, 21 male) without any known ocular disease were used. Ocular tissues were prepared under a dissecting microscope and were snap frozen in liquid nitrogen. The presence of characteristic exfoliation material deposits was assessed by macroscopic inspection of anterior segment structures and confirmed by electron microscopy analysis of small tissue sectors.
For immunostaining experiments, ocular tissue samples obtained from 10 donor eyes with XFS (mean age, 78.7 ± 9.7 years; 6 female, 4 male) and 10 normal human donor eyes (mean age, 72.3 ± 11.6 years; 5 female, 5 male) were embedded in optimal cutting temperature compound and frozen in liquid nitrogen. DNA samples obtained from ocular tissues and cells were genotyped by Sanger sequencing (Supplementary Note). The ethical review boards of the medical faculties of the University of Erlangen-Nuremberg, the University of Tübingen and the University of Würzburg, as well as the local ethics committee (4218-CH), approved this study.
Quantitative real-time PCR of human eye tissues. Ocular tissues were extracted using the Precellys 24 homogenizer and lysing kit together with the AllPrep DNA/RNA kit (Qiagen) according to the manufacturer's instructions. This includes an on-column DNase I digestion step. First-strand cDNA synthesis from 0.5 µg of total RNA was performed with Superscript II reverse transcriptase (Invitrogen) in a 20 µl reaction volume. Quantitative real-time PCR was performed using the CFX Connect thermal cycler and software (BioRad). PCR reactions (25 µl) were run in duplicate and contained 2 µl of firststrand cDNA, 0.4 µM of each upstream and downstream primer, and SsoFast EvaGreen Supermix (Bio-Rad). The sequences for the exon-spanning primers (Eurofins Genomics), designed using Primer3 software (see URLs), and PCR conditions are appended in Supplementary Table 16 . For normalization of gene expression levels, mRNA ratios relative to the housekeeping gene GAPDH were calculated by the comparative C T method ( 2 −∆C T ). Amplification specificity was checked using melt curve and sequence analyses on the Prism 3100 DNA sequencer (Applied Biosystems).
Immunoblot analysis of human eye tissues. Total protein was extracted from the iris and ciliary body tissues of six eyes with XFS and six normal eyes using RIPA buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% DOC, 0.1% SDS). Protein concentrations were determined with the Micro-BCA protein assay kit (Thermo Scientific). Proteins (10 µg per lane) were separated by 4-15% SDS-PAGE under reducing conditions (6% DTT) and transferred onto nitrocellulose membranes with the Trans-Blot Turbo transfer system (Bio-Rad). Membranes were blocked with SuperBlock T20 (Thermo Scientific) for 30 min and incubated for 1 h at room temperature or overnight at 4 °C with antibodies against POMP (ab170865, Abcam) and TMEM136 (ab182495, Abcam) diluted in 10% SuperBlock T20 in PBST. Equal loading was verified with mouse antibody to human β-actin (clone AC-15, Sigma-Aldrich) in 10% SuperBlock T20 in PBST. In negative-control experiments, the primary antibody was replaced by PBST. Immunodetection was performed with a horseradish peroxidase (HRP)-conjugated secondary antibody in 10% SuperBlock T20 in PBST and the Super Signal West Femto ECL kit (Thermo Scientific), and band intensity was analyzed by computerized densitometry. Immunohistochemistry of human eye tissues followed routine laboratory procedures, which are described in the Supplementary Note. LOXL1 constructs. The full-length cDNA encoding LOXL1 was amplified using the primers shown in Supplementary Table 16 . The restriction enzyme sites EcoRI and SalI were added in a second amplification using a second set of primers (Supplementary Table 17 ). The LOXL1 fragment (~1.7 kb) was then subcloned into a pcipuro vector encoding an HA tag. Four haplotypes, Arg141-Gly153-Tyr407 (G-G-A), Leu141-Gly153-Tyr407 (T-G-A), Arg141-Asp153-Tyr407 (G-A-A) and Arg141-Asp153-Phe407 (G-A-T), were generated and contained genetic variants in the following order: rs1048661[G>T]-rs3825942[G>A]-rs201011613[A>T]. The first haplotype generated was Arg141-Asp153-Tyr407 (G-A-A), and this served as the template plasmid for subsequent site-directed mutagenesis.
Targeted base substitution was achieved by site-directed mutagenesis using a PCR-based strategy using the Transformer site-directed mutagenesis kit (Clontech) with respective oligonucleotide primer pairs (Supplementary  Table 17 ) on the LOXL1 Arg141-Asp153-Tyr407 (G-A-A) haplotype. The accuracy of all the haplotypes constructed was confirmed by Sanger sequencing of the full-length clone. All oligonucleotide primer pairs used to create the LOXL1 constructs are appended in Supplementary Table 17. Nano luciferase secretion assay for LOXL1. The secretion assay for LOXL1 with respect to the four tested haplotypes Arg141-Gly153-Tyr407 (G-G-A), Leu141-Gly153-Tyr407 (T-G-A), Arg141-Asp153-Tyr407 (G-A-A) and Arg141-Asp153-Phe407 (G-A-T) was performed using the NanoLuc luciferase assay. More details for this assay are appended in the Supplementary Note.
Immunoblot analysis of the different HA-tagged LOXL1 haplotypes on elastin, fibronectin and collagen IV followed routine laboratory procedures, which are appended in the Supplementary Note. Spheroid cultures. The HLEC (B-3) cell line was obtained from the American Type Culture Collection (ATCC). Cells were maintained in DMEM supplemented with 20% FBS (Sigma-Aldrich) and 2 mM GLUTAMAX (Invitrogen) at 37 °C with 5% CO 2 and were passaged every 2-3 d in a 1:4 ratio. The cell line was tested for mycoplasma and was found to be negative.
Nucleofected HLECs were trypsinized 48 h after nucleofection and seeded in their growth medium in low-attachment six-well plates with hydrophobic surfaces (Greiner Bio-One) at 300,000 cells per well. Cells were left to form spheroids and were collected at 72 h. The spheroids were fixed with 4% paraformaldehyde for 10 min at room temperature and stored at 4 °C. Fixed spheroids were washed with PBST (0.1% Tween-20 in 1× PBS) and blocked in blocking buffer (3% BSA in PBS) for 1 h at room temperature. They were subsequently incubated overnight at 4 °C with the following primary antibodies: mouse or rabbit antibody to HA (1:100 dilution; sc-7392 and sc-805, Santa Cruz Biotechnology), goat antibody to elastin (1:100 dilution; sc-17581, Santa Cruz Biotechnology), mouse antibody to fibrillin-1
